Who Owns Viagra?

Viagra's sustainability practices operate within Viatris's global sustainability framework, which focuses on environmental stewardship, reliable supply, patient access, and ethical governance.

Climate Targets: Viatris has set Science Based Targets to reduce absolute scope 1 and 2 greenhouse gas emissions by 42% and scope 3 emissions by 25% by 2030 from a 2020 baseline. Through the end of 2025, the company achieved a 17% reduction in scope 1 and 2 emissions and a 36% reduction in scope 3 emissions, exceeding its scope 3 target. Viatris's Sandwich, UK facility transitioned to 100% renewable energy in 2025.

Zero Waste to Landfill: Viatris achieved zero waste to landfill status at 17 sites across its network as of 2025, exceeding its target of a 50% increase in ZWL locations by 2030. All manufacturing and packaging operations in Europe achieved ZWL status, including facilities in France, Hungary, Germany, and Ireland.

Patient Access Programs: Viatris operates patient access programs for Viagra and other medications to ensure patients can access treatments regardless of their ability to pay. These programs include financial assistance, copay support, and patient education services. Viatris supplied high-quality medicines to approximately 1 billion patients worldwide in 2024.

Supply Chain Responsibility: Viatris maintains responsible supply chain practices for Viagra, including quality assurance agreements with suppliers, ethical sourcing of raw materials, and temperature-controlled logistics. The company's supply chain management includes environmental considerations and social responsibility standards for all suppliers.

Sustainability Recognition: Viatris was named to TIME's World's Most Sustainable Companies 2026 list and Newsweek's World's Greenest Companies list, reflecting its commitment to responsible operations while building sustainable access to medicines at scale.

Viagra has received recognition within the pharmaceutical and medical communities for its innovation in men's health treatment and its cultural impact on sexual health discourse.

• FDA First Approval (1998): Viagra's FDA approval on March 27, 1998, as the first oral erectile dysfunction treatment was recognized as a landmark in pharmaceutical innovation. The approval addressed the limitations of existing invasive treatments and provided a convenient oral option for millions of men
• PDE5 Inhibitor Pioneer: Viagra's development as the first oral PDE5 inhibitor has been recognized by pharmaceutical and medical organizations as an innovative approach to men's health treatment, advancing the science of sexual health medicine
• Cultural Impact: Viagra's role in destigmatizing discussions about erectile dysfunction and sexual health has been recognized by social science and medical humanities organizations. The drug's launch in 1998 generated $788 million in first-year sales and became a cultural phenomenon
• Patient Safety Track Record: Viagra's established safety profile, with more than 25 years of post-approval data from tens of millions of patients, has been recognized by patient safety organizations. The drug's long safety record demonstrates excellence in pharmaceutical post-marketing surveillance
• PAH Dose Expansion (2024): The FDA updated sildenafil labeling for pulmonary arterial hypertension in 2024 based on a multicenter study, allowing dose titration to 80 mg three times daily and withdrawing the 5 mg dose recommendation. This regulatory update expanded the therapeutic options for PAH patients

Viagra has maintained a strong safety profile since its 1998 approval, though the brand and its parent company have faced challenges related to manufacturing quality, counterfeit products, and market competition.

FDA Warning Letter for Indore Facility (December 2024): The FDA issued a warning letter to Viatris on December 19, 2024, following an inspection of its Mylan Laboratories Limited facility in Indore, India, from June 14 to 26, 2024. The FDA cited significant violations of Current Good Manufacturing Practice regulations, including poor quality control, data integrity issues, and inadequate handling of manufacturing errors. The FDA restricted imports of 11 products from the facility into the United States, with conditional exceptions for four products based on shortage concerns. Viatris implemented a comprehensive remediation plan and engaged third-party consultants. The Indore facility does not manufacture Viagra, but the warning letter affected Viatris's broader manufacturing operations and 2025 financial guidance by approximately $500 million in lost revenue.

Counterfeit Products: Viagra faces ongoing challenges with counterfeit products sold through unauthorized online channels. In February 2026, the FDA warned consumers about multiple products including Fantasy Aphrodisiac Chocolate, Boner Bears Chocolate Bars, and LOVION Chocolate with Ginseng, all found to contain undeclared sildenafil. In January 2026, Health Canada seized counterfeit Viagra and Cialis from Bitco Distribution in Mississauga, Ontario. In February 2026, the DEA announced Operation Meltdown, shutting down over 200 illegal online pharmacies tied to an India-based organization. These counterfeit products pose significant safety risks to patients and enforcement challenges for Viatris and regulatory agencies.

Generic Competition Impact: The expiry of Viagra's U.S. patent in 2017 and the subsequent availability of generic sildenafil from over 15 manufacturers at a fraction of the cost of branded Viagra significantly reduced the brand's U.S. market share. Generic sildenafil captured the majority of sildenafil prescriptions in the United States. Branded Viagra's 2025 net sales of $408.2 million represent a fraction of the peak sales of approximately $2 billion in the mid-2000s.

Viatris Enterprise-Wide Strategic Review (2026): In February 2026, Viatris announced the results of its enterprise-wide strategic review, including a global workforce reduction of up to 10% over three years and restructuring charges of $700 million to $850 million. While this restructuring affects Viatris's overall operations rather than Viagra specifically, it creates uncertainty about long-term commercial investment in individual branded products.

Insurance Coverage Variability: Insurance coverage for Viagra varies significantly across different healthcare systems and insurance plans, creating access barriers for some patients. This coverage variability reflects broader healthcare policy and insurance industry practices rather than issues specific to Viagra.